Bit Bio

bit.bio is a synthetic biology company providing human cells for research, drug discovery and cell therapy. The company applies a patented safe harbour gene-targeting approach (opti-ox™; Pawlowski 2017) to inducibly express transcription factor combinations that reprogram human induced pluripotent stem cells (iPSCs) into highly defined and mature human cell types.

Morgan Prestwich were retained to appoint the following positions:
- VP Business Development
- VP Scientific Affairs
- Snr Director Clinical Development